聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 1 小时 14 分钟 前

SharedClarity Awards First Contracts

周二, 03/04/2014 - 16:29
Medtronic, Abbott to Provide Bare Metal and Drug-Eluting Stents PHOENIX--(Healthcare Sales & Marketing Network)--SharedClarity announced today its first contract awards, with Medtronic and Abbott chosen to provide bare metal and drug-eluting stents to S...
Devices, Interventional Cardiology, Group Purchasing
SharedClarity, Medtronic, Abbott, drug-eluting stent

Contextual Genomics Appoints Chris Wagner as President and CEO

周二, 03/04/2014 - 16:26
VANCOUVER, British Columbia--(Healthcare Sales & Marketing Network)--Contextual Genomics, a next generation molecular diagnostics company, announced today that Chris Wagner has been appointed President and Chief Executive Officer. “We are very pleased t...
Diagnostics, Oncology, Cardiology, Personnel
Contextual Genomics

Pernix Therapeutics Appoints Vice President of Compliance

周二, 03/04/2014 - 13:06
HOUSTON--(Healthcare Sales & Marketing Network)--Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced the appointment of Jessica Oien as Vice President of Compliance. “As we continue to focus on growing our busin...
Biopharmaceuticals, Personnel
Pernix Therapeutics Holdings

Atossa Genetics Inc. Announces FDA Response to 510(k) Submission for ForeCYTE Breast Aspirator

周二, 03/04/2014 - 13:04
SEATTLE, WA--(Healthcare Sales & Marketing Network) - Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has received a request for additional information from the U.S. Food and Drug Administration (FDA) related to its 510(k) application for the F...
Devices, Diagnostics, Oncology, FDA
Atossa Genetics, ForeCYTE, Breast Aspirator

Neos Therapeutics Completes $15.5 Million Additional Series C Financing

周二, 03/04/2014 - 12:56
DALLAS/FORT WORTH, Texas--(Healthcare Sales & Marketing Network)--Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of inno...
Biopharmaceuticals, Drug Delivery, Venture Capital
Neos Therapeutics

Cell Migration Enhanced with Procellera(R) Wireless Microcurrent Generating Wound Dressing

周二, 03/04/2014 - 12:40
Groundbreaking Study Published in PLOS ONE Unveils Substantial Potential of Bioelectriceuticals in Wound Care and Beyond TEMPE, Ariz., March 4, 2014 -- (Healthcare Sales & Marketing Network) -- Procellera® – the world's first wireless microcurrent ...
Devices, Wound Care
Vomaris Wound Care, Procellera, microcell batteries, wound dressing

Invuity(R) Raises $36 Million in Series E Financing

周二, 03/04/2014 - 12:34
SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Invuity, Inc., a developer of advanced medical devices to dramatically improve access and visualization in minimally invasive and minimal access surgeries, announced today that it has secured $36 milli...
Devices, Surgery, Venture Capital
Invuity, Eigr

ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA(R) in the US

周二, 03/04/2014 - 12:28
Ocriplasmin Research to Better Inform Treatment (ORBIT) study designed to generate further data on the "real world" use of JETREA® LEUVEN, Belgium, March 4, 2014 -- (Healthcare Sales & Marketing Network) --ThromboGenics NV (Euronext Bruss...
Biopharmaceuticals, Ophthalmology
ThromboGenics, Ocriplasmin, JETREA, vitreomacular adhesion

Visian(R) ICL(TM) with CentraFLOW(R) Approved to Market in Japan

周一, 03/03/2014 - 21:52
Over 50,000 ICLs Successfully Implanted with CentraFLOW Driven by the KS-AquaPORT Technology™ MONROVIA, Calif., March 3, 2014 -- (Healthcare Sales & Marketing Network) -- STAAR Surgical Company (STAA), a leading developer, manufacturer and marketer of ...
Devices, Ophthalmology, Regulatory
STAAR Surgical, Visian, Implantable Collamer Lens, CentraFLOW

BioRestorative Therapies Names Gregory Lutz, M.D. as Chief Medical Advisor for Spine Medicine

周一, 03/03/2014 - 21:47
Dr. Lutz, Physiatrist-in-Chief Emeritus for the Hospital for Special Surgery, assumes responsibility for clinical aspects of the brtxDISC™ Program JUPITER, Fla.--(Healthcare Sales & Marketing Network)--BioRestorative Therapies, Inc. ("BRT" or ...
Regenerative Medicine, Personnel
BioRestorative Therapies

Vansen Pharma Inc. appoints new President and CEO

周一, 03/03/2014 - 21:42
LAS VEGAS, March 3, 2014 -- (Healthcare Sales & Marketing Network) - Vansen Pharma Inc. [OTCQB: VNSN], a specialty pharmaceutical company, is pleased to announce the appointment of Dr. Ahmad Doroudian as its President and Chief Executive Officer. Dr. Doro...
Biopharmaceuticals, Personnel
Vansen Pharma

PaxVax Announces New Commercial Senior Leadership Appointments

周一, 03/03/2014 - 15:31
New Hires Expand Senior Management Team Ahead of Anticipated Cholera Vaccine Launch MENLO PARK, Calif. & SAN DIEGO--(Healthcare Sales & Marketing Network)--PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a socia...
Biopharmaceuticals, Personnel
PaxVax, vaccine

Covidien Announces CE Mark Approval for Puritan Bennett(TM) 980 Ventilator

周一, 03/03/2014 - 15:05
New acute care ventilator delivers advanced breath technology for enhanced patient comfort and clinician ease of use DUBLIN, Ireland--(Healthcare Sales & Marketing Network)--Covidien plc (COV), a leading global provider of healthcare products and recogn...
Devices, Regulatory
Covidien, Puritan Bennett

Myriad Publishes Clinical Utility Study for Prolaris(R)

周一, 03/03/2014 - 13:37
Myriad Submits Updated Dossier for Medicare Reimbursement SALT LAKE CITY, March 3, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Curren...
Diagnostics, Urology
Myriad Genetics, Prolaris test, prostate cancer

U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

周一, 03/03/2014 - 13:30
WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--AstraZeneca (AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to die...
Biopharmaceuticals, Drug Delivery, Endocrinology, FDA
AstraZeneca, Bydureon Pen, exenatide, diabetes

Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer

周一, 03/03/2014 - 13:17
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that an independent data monitoring committee has recommended that the Phase III METLung study be stop...
Biopharmaceuticals, Oncology
Genentech, METLung study, onartuzumab, MetMab, NSCLC

Knight Therapeutics Inc. Appoints New CFO

周五, 02/28/2014 - 16:14
MONTREAL, CANADA--(Healthcare Sales & Marketing Network) - Knight Therapeutics Inc. (TSX VENTURE:GUD) ("Knight") announced today that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Pr...
Biopharmaceuticals, Personnel
Knight Therapeutics

GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome

周五, 02/28/2014 - 13:16
LONDON, Feb. 28, 2014 -- (Healthcare Sales & Marketing Network) -- GW Pharmaceuticals plc (GWP.L) (GWPH) ("GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex(R), GW's product ca...
Biopharmaceuticals, FDA
GW Pharmaceuticals, orphan drug designation, Epidiolex, Lennox-Gastaut

Abingworth Raises £225m ($375m) in its Tenth Life Sciences Fund

周五, 02/28/2014 - 12:06
LONDON, February 28, 2014 -- (Healthcare Sales & Marketing Network) --Abingworth, the international investment group dedicated to life sciences and healthcare, today announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (A...
Biopharmaceuticals, Devices, Venture Capital
Abingworth, Abingworth Bioventures, Avedro, eFFECTOR, GenSight Biologics

InterMune(R) Announces Support for First Ever European Patient Charter on Idiopathic Pulmonary Fibrosis (IPF)

周五, 02/28/2014 - 11:58
MUTTENZ, Switzerland, February 28, 2014 -- (Healthcare Sales & Marketing Network) --To mark international Rare Disease Day, InterMune today announces its support for the development of a European Patient Charter for people with idiopathic pulmonary fibros...
Biopharmaceuticals
InterMune, idiopathic pulmonary fibrosis

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong